Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

被引：31
|
作者：
Coombs, Catherine C. [1 ]
Sallman, David A. [2 ]
Devlin, Sean M. [3 ]
Dixit, Shweta
Mohanty, Abhinita [5 ]
Knapp, Kristina [4 ]
Al Ali, Najla H. [2 ]
Lancet, Jeffrey E. [2 ]
List, Alan F. [2 ]
Komrokji, Rami S. [2 ]
Padron, Eric [2 ]
Arcila, Maria E. [5 ]
Klimek, Virginia M. [1 ]
van den Brink, Marcel R. M. [6 ]
Tallman, Martin S. [1 ,7 ]
Levine, Ross L. [1 ,4 ]
Rampal, Raajit K. [1 ]
Rapaport, Franck [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA
[7] Weill Cornell Med Coll, New York, NY USA
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 11期
关键词：
OLDER PATIENTS; AZACITIDINE; PHENOTYPE; DNMT3A; IMPACT; IDH2; CARE; AML;
D O I：
10.3324/haematol.2016.148999
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E457 / E460
页数：4
相关论文
共 50 条
  • [1] Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway
    Coombs, Catherine C.
    Devlin, Sean
    Dixit, Shweta
    Mohanty, Abhinita
    Knapp, Kristina Marie
    Arcila, Maria
    Klimek, Virginia M.
    Tallman, Martin S.
    Levine, Ross L.
    Rampal, Raajit K.
    Rapaport, Franck
    BLOOD, 2015, 126 (23)
  • [2] Time to response and survival in hypomethylating agent-treated acute myeloid leukemia
    Boddu, Prajwal
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    Daver, Naval
    Pemmaraju, Naveen
    Pierce, Sherry
    Cortes, Jorge
    Kadia, Tapan M.
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 1012 - 1015
  • [3] Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm
    Tremblay, Douglas
    Feld, Jonathan
    Dougherty, Mikaela
    Czaplinska, Tina
    Sanchez, Gillian
    Kremyanskaya, Marina
    Bar-Natan, Michal
    Shih, Alan H.
    Keyzner, Alla
    Mascarenhas, John
    LEUKEMIA RESEARCH, 2020, 98
  • [4] DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
    Metzeler, K. H.
    Walker, A.
    Geyer, S.
    Garzon, R.
    Klisovic, R. B.
    Bloomfield, C. D.
    Blum, W.
    Marcucci, G.
    LEUKEMIA, 2012, 26 (05) : 1106 - 1107
  • [5] DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
    K H Metzeler
    A Walker
    S Geyer
    R Garzon
    R B Klisovic
    C D Bloomfield
    W Blum
    G Marcucci
    Leukemia, 2012, 26 : 1106 - 1107
  • [6] Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival
    Niyongere, Sandrine
    Kathari, Yamini
    Singh, Zeba
    Vannorsdall, Emily J.
    Emadi, Ashkan
    Vu Doung
    Baer, Maria R.
    BLOOD, 2020, 136
  • [7] Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna
    Naidoo, Nuthana
    Lombardi, Jennifer
    Pullarkat, Vinod
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : E59 - E63
  • [8] Oral Azacitidine Maintenance Therapy in Acute Myeloid Leukemia after Frontline Hypomethylating Agent and Venetoclax
    Canavan, Cody
    Knight, Thomas G.
    Shah, Nilay A.
    Chojecki, Aleksander L.
    Ai, Jing
    Levine, Jonathan K.
    Osei-Boateng, Kwabena
    Hiremath, Adarsh
    Grunwald, Michael R.
    BLOOD, 2024, 144 : 6036 - 6037
  • [9] Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes
    Kim, Kunhwa
    Ong, Faustine
    Li, Ziyi
    Shamanna, Rashmi Kanagal
    Bravo, Guillermo Montalban
    Kadia, Tapan
    Jabbour, Elias
    Pemmaraju, Naveen
    Hammond, Danielle
    Short, Nicholas
    Ravandi, Farhad
    Alvarado, Yesid
    Pierce, Sherry
    Dong, Xiao Qin
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Chien, Kelly
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S313 - S314
  • [10] Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia
    Singh, Reema
    Halder, Rohan
    Verma, Megha
    Mehta, Pallavi
    Agrawal, Narendra
    Ahmed, Rayaz
    Bhurani, Dinesh
    BLOOD, 2022, 140 : 11713 - 11715
12345